Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 3.3%

Tyra Biosciences, Inc. (NASDAQ:TYRAGet Rating)’s share price was down 3.3% on Thursday . The stock traded as low as $8.83 and last traded at $9.02. Approximately 52,316 shares changed hands during mid-day trading, a decline of 41% from the average daily volume of 88,450 shares. The stock had previously closed at $9.33.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright started coverage on Tyra Biosciences in a report on Thursday, June 23rd. They issued a “buy” rating and a $12.00 price objective for the company.

Tyra Biosciences Stock Performance

The company has a 50 day simple moving average of $8.13 and a two-hundred day simple moving average of $9.66.

Tyra Biosciences (NASDAQ:TYRAGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.16). As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.35 earnings per share for the current year.

Institutional Trading of Tyra Biosciences

Institutional investors have recently made changes to their positions in the stock. Strs Ohio acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth approximately $39,000. Bailard Inc. acquired a new stake in shares of Tyra Biosciences during the second quarter worth approximately $92,000. New York State Common Retirement Fund acquired a new stake in shares of Tyra Biosciences during the first quarter worth approximately $113,000. Rhumbline Advisers acquired a new stake in shares of Tyra Biosciences during the first quarter worth approximately $125,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Tyra Biosciences by 48.8% during the first quarter. Bank of New York Mellon Corp now owns 30,620 shares of the company’s stock worth $328,000 after purchasing an additional 10,045 shares during the period. 99.96% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

(Get Rating)

Tyra Biosciences, Inc, a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.

Featured Articles

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.